CYP3A4 and acute kidney injury: These results demonstrated that coprescription of CYP3A4-metabolized statin and CCBs that inhibit CYP3A4 independently contributed to acute kidney injury, hyperkalemia, acute myocardial infarction, and acute ischemic stroke.